<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
    <PubmedArticle>
        <MedlineCitation Status="MEDLINE" Owner="NLM">
            <PMID Version="1">30545708</PMID>
            <DateCompleted>
                <Year>2019</Year>
                <Month>12</Month>
                <Day>26</Day>
            </DateCompleted>
            <DateRevised>
                <Year>2024</Year>
                <Month>06</Month>
                <Day>07</Day>
            </DateRevised>
            <Article PubModel="Print-Electronic">
                <Journal>
                    <ISSN IssnType="Electronic">1523-6838</ISSN>
                    <JournalIssue CitedMedium="Internet">
                        <Volume>73</Volume>
                        <Issue>3</Issue>
                        <PubDate>
                            <Year>2019</Year>
                            <Month>Mar</Month>
                        </PubDate>
                    </JournalIssue>
                    <Title>American journal of kidney diseases : the official journal of the National Kidney Foundation</Title>
                    <ISOAbbreviation>Am J Kidney Dis</ISOAbbreviation>
                </Journal>
                <ArticleTitle>Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients With CKD: Findings From the CRIC Study.</ArticleTitle>
                <Pagination>
                    <StartPage>344</StartPage>
                    <EndPage>353</EndPage>
                    <MedlinePgn>344-353</MedlinePgn>
                </Pagination>
                <ELocationID EIdType="doi" ValidYN="Y">10.1053/j.ajkd.2018.09.012</ELocationID>
                <ELocationID EIdType="pii" ValidYN="Y">S0272-6386(18)31039-4</ELocationID>
                <Abstract>
                    <AbstractText Label="RATIONALE &amp; OBJECTIVE">Traditional risk estimates for atherosclerotic vascular disease (ASVD) and death may not perform optimally in the setting of chronic kidney disease (CKD). We sought to determine whether the addition of measures of inflammation and kidney function to traditional estimation tools improves prediction of these events in a diverse cohort of patients with CKD.</AbstractText>
                    <AbstractText Label="STUDY DESIGN">Observational cohort study.</AbstractText>
                    <AbstractText Label="SETTING &amp; PARTICIPANTS">2,399 Chronic Renal Insufficiency Cohort (CRIC) Study participants without a history of cardiovascular disease at study entry.</AbstractText>
                    <AbstractText Label="PREDICTORS">Baseline plasma levels of biomarkers of inflammation (interleukin 1&#x3b2; [IL-1&#x3b2;], IL-1 receptor antagonist, IL-6, tumor necrosis factor &#x3b1; [TNF-&#x3b1;], transforming growth factor &#x3b2;, high-sensitivity C-reactive protein, fibrinogen, and serum albumin), measures of kidney function (estimated glomerular filtration rate [eGFR] and albuminuria), and the Pooled Cohort Equation probability (PCEP) estimate.</AbstractText>
                    <AbstractText Label="OUTCOMES">Composite of ASVD events (incident myocardial infarction, peripheral arterial disease, and stroke) and death.</AbstractText>
                    <AbstractText Label="ANALYTICAL APPROACH">Cox proportional hazard models adjusted for PCEP estimates, albuminuria, and eGFR.</AbstractText>
                    <AbstractText Label="RESULTS">During a median follow-up of 7.3 years, 86, 61, 48, and 323 participants experienced myocardial infarction, peripheral arterial disease, stroke, or death, respectively. The 1-decile greater levels of IL-6 (adjusted HR [aHR], 1.12; 95% CI, 1.08-1.16; P&lt;0.001), TNF-&#x3b1; (aHR, 1.09; 95% CI, 1.05-1.13; P&lt;0.001), fibrinogen (aHR, 1.07; 95% CI, 1.03-1.11; P&lt;0.001), and serum albumin (aHR, 0.96; 95% CI, 0.93-0.99; P&lt;0.002) were independently associated with the composite ASVD-death outcome. A composite inflammation score (CIS) incorporating these 4 biomarkers was associated with a graded increase in risk for the composite outcome. The incidence of ASVD-death increased across the quintiles of risk derived from PCEP, kidney function, and CIS. The addition of eGFR, albuminuria, and CIS to PCEP improved (P=0.003) the area under the receiver operating characteristic curve for the composite outcome from 0.68 (95% CI, 0.66-0.71) to 0.73 (95% CI, 0.71-0.76).</AbstractText>
                    <AbstractText Label="LIMITATIONS">Data for cardiovascular death were not available.</AbstractText>
                    <AbstractText Label="CONCLUSIONS">Biomarkers of inflammation and measures of kidney function are independently associated with incident ASVD events and death in patients with CKD. Traditional cardiovascular risk estimates could be improved by adding markers of inflammation and measures of kidney function.</AbstractText>
                    <CopyrightInformation>Copyright &#xa9; 2018 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Amdur</LastName>
                        <ForeName>Richard L</ForeName>
                        <Initials>RL</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Surgery, George Washington University, Washington, DC.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Feldman</LastName>
                        <ForeName>Harold I</ForeName>
                        <Initials>HI</Initials>
                        <AffiliationInfo>
                            <Affiliation>Renal Electrolyte and Hypertension Division, University of Pennsylvania, PA; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, PA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Dominic</LastName>
                        <ForeName>Elizabeth A</ForeName>
                        <Initials>EA</Initials>
                        <AffiliationInfo>
                            <Affiliation>Georgetown University School of Medicine, Washington, DC.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Anderson</LastName>
                        <ForeName>Amanda H</ForeName>
                        <Initials>AH</Initials>
                        <AffiliationInfo>
                            <Affiliation>Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, PA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Beddhu</LastName>
                        <ForeName>Srinivasan</ForeName>
                        <Initials>S</Initials>
                        <AffiliationInfo>
                            <Affiliation>Division of Nephrology, University of Utah School of Medicine, Salt Lake City, UT.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Rahman</LastName>
                        <ForeName>Mahboob</ForeName>
                        <Initials>M</Initials>
                        <AffiliationInfo>
                            <Affiliation>Division of Nephrology and Hypertension, Case Western Reserve University, OH.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Wolf</LastName>
                        <ForeName>Myles</ForeName>
                        <Initials>M</Initials>
                        <AffiliationInfo>
                            <Affiliation>Division of Nephrology, Duke University, Durham, NC.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Reilly</LastName>
                        <ForeName>Muredach</ForeName>
                        <Initials>M</Initials>
                        <AffiliationInfo>
                            <Affiliation>Cardiology Division, Department of Medicine and the Irving Institute for Clinical and Translational Research, Columbia University College of Physician and Surgeon, New York, NY.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Ojo</LastName>
                        <ForeName>Akinlolu</ForeName>
                        <Initials>A</Initials>
                        <AffiliationInfo>
                            <Affiliation>University of Arizona School of Medicine, Tucson, AZ.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Townsend</LastName>
                        <ForeName>Raymond R</ForeName>
                        <Initials>RR</Initials>
                        <AffiliationInfo>
                            <Affiliation>Renal Electrolyte and Hypertension Division, University of Pennsylvania, PA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Go</LastName>
                        <ForeName>Alan S</ForeName>
                        <Initials>AS</Initials>
                        <AffiliationInfo>
                            <Affiliation>Kaiser Permanente Division of Research, Oakland, CA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>He</LastName>
                        <ForeName>Jiang</ForeName>
                        <Initials>J</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Epidemiology, Tulane University, LA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Xie</LastName>
                        <ForeName>Dawei</ForeName>
                        <Initials>D</Initials>
                        <AffiliationInfo>
                            <Affiliation>Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, PA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Thompson</LastName>
                        <ForeName>Sally</ForeName>
                        <Initials>S</Initials>
                        <AffiliationInfo>
                            <Affiliation>Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, PA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Budoff</LastName>
                        <ForeName>Matthew</ForeName>
                        <Initials>M</Initials>
                        <AffiliationInfo>
                            <Affiliation>Division of Cardiology, Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Kasner</LastName>
                        <ForeName>Scott</ForeName>
                        <Initials>S</Initials>
                        <AffiliationInfo>
                            <Affiliation>Division of Vascular Neurology, University of Pennsylvania, PA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Kimmel</LastName>
                        <ForeName>Paul L</ForeName>
                        <Initials>PL</Initials>
                        <AffiliationInfo>
                            <Affiliation>Division of Kidney Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Kusek</LastName>
                        <ForeName>John W</ForeName>
                        <Initials>JW</Initials>
                        <AffiliationInfo>
                            <Affiliation>Division of Kidney Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Raj</LastName>
                        <ForeName>Dominic S</ForeName>
                        <Initials>DS</Initials>
                        <AffiliationInfo>
                            <Affiliation>Division of Kidney Diseases and Hypertension, George Washington University, Washington, DC. Electronic address: draj@mfa.gwu.edu.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <CollectiveName>CRIC Study Investigators</CollectiveName>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <GrantList CompleteYN="Y">
                    <Grant>
                        <GrantID>UL1 TR002548</GrantID>
                        <Acronym>TR</Acronym>
                        <Agency>NCATS NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>U01 DK060963</GrantID>
                        <Acronym>DK</Acronym>
                        <Agency>NIDDK NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>UL1 RR024131</GrantID>
                        <Acronym>RR</Acronym>
                        <Agency>NCRR NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>U01 DK099924</GrantID>
                        <Acronym>DK</Acronym>
                        <Agency>NIDDK NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>U01 DK061022</GrantID>
                        <Acronym>DK</Acronym>
                        <Agency>NIDDK NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>UL1 TR000003</GrantID>
                        <Acronym>TR</Acronym>
                        <Agency>NCATS NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>UL1 TR000439</GrantID>
                        <Acronym>TR</Acronym>
                        <Agency>NCATS NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>U01 DK060990</GrantID>
                        <Acronym>DK</Acronym>
                        <Agency>NIDDK NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>R01 DK073665</GrantID>
                        <Acronym>DK</Acronym>
                        <Agency>NIDDK NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>UL1 RR029879</GrantID>
                        <Acronym>RR</Acronym>
                        <Agency>NCRR NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>U01 DK061028</GrantID>
                        <Acronym>DK</Acronym>
                        <Agency>NIDDK NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>UL1 TR000433</GrantID>
                        <Acronym>TR</Acronym>
                        <Agency>NCATS NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>U01 DK060984</GrantID>
                        <Acronym>DK</Acronym>
                        <Agency>NIDDK NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>U01 DK061021</GrantID>
                        <Acronym>DK</Acronym>
                        <Agency>NIDDK NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>U24 DK060990</GrantID>
                        <Acronym>DK</Acronym>
                        <Agency>NIDDK NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>U01 DK060980</GrantID>
                        <Acronym>DK</Acronym>
                        <Agency>NIDDK NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>UL1 TR000424</GrantID>
                        <Acronym>TR</Acronym>
                        <Agency>NCATS NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>M01 RR016500</GrantID>
                        <Acronym>RR</Acronym>
                        <Agency>NCRR NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>U01 DK099914</GrantID>
                        <Acronym>DK</Acronym>
                        <Agency>NIDDK NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>P20 GM109036</GrantID>
                        <Acronym>GM</Acronym>
                        <Agency>NIGMS NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>U01 DK060902</GrantID>
                        <Acronym>DK</Acronym>
                        <Agency>NIDDK NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                    <Grant>
                        <GrantID>UL1 TR002003</GrantID>
                        <Acronym>TR</Acronym>
                        <Agency>NCATS NIH HHS</Agency>
                        <Country>United States</Country>
                    </Grant>
                </GrantList>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                    <PublicationType UI="D064888">Observational Study</PublicationType>
                    <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                </PublicationTypeList>
                <ArticleDate DateType="Electronic">
                    <Year>2018</Year>
                    <Month>12</Month>
                    <Day>10</Day>
                </ArticleDate>
            </Article>
            <MedlineJournalInfo>
                <Country>United States</Country>
                <MedlineTA>Am J Kidney Dis</MedlineTA>
                <NlmUniqueID>8110075</NlmUniqueID>
                <ISSNLinking>0272-6386</ISSNLinking>
            </MedlineJournalInfo>
            <ChemicalList>
                <Chemical>
                    <RegistryNumber>0</RegistryNumber>
                    <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
                </Chemical>
            </ChemicalList>
            <CitationSubset>IM</CitationSubset>
            <MeshHeadingList>
                <MeshHeading>
                    <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D050197" MajorTopicYN="N">Atherosclerosis</DescriptorName>
                    <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
                    <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
                    <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D007677" MajorTopicYN="N">Kidney Function Tests</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D051436" MajorTopicYN="N">Renal Insufficiency, Chronic</DescriptorName>
                    <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                    <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
                    <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                    <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
                </MeshHeading>
            </MeshHeadingList>
            <KeywordList Owner="NOTNLM">
                <Keyword MajorTopicYN="N">C-reactive protein (CRP)</Keyword>
                <Keyword MajorTopicYN="N">Myocardial infarction (MI)</Keyword>
                <Keyword MajorTopicYN="N">Pooled Cohort Equation probability (PCEP)</Keyword>
                <Keyword MajorTopicYN="N">albuminuria</Keyword>
                <Keyword MajorTopicYN="N">atherosclerosis</Keyword>
                <Keyword MajorTopicYN="N">atherosclerotic vascular disease (ASVD)</Keyword>
                <Keyword MajorTopicYN="N">cardiovascular disease (CVD)</Keyword>
                <Keyword MajorTopicYN="N">chronic kidney function (CKD)</Keyword>
                <Keyword MajorTopicYN="N">cytokines</Keyword>
                <Keyword MajorTopicYN="N">estimated glomerular filtration rate (eGFR)</Keyword>
                <Keyword MajorTopicYN="N">inflammatory biomarkers</Keyword>
                <Keyword MajorTopicYN="N">kidney function</Keyword>
                <Keyword MajorTopicYN="N">risk stratification</Keyword>
                <Keyword MajorTopicYN="N">stroke</Keyword>
            </KeywordList>
            <InvestigatorList>
                <Investigator ValidYN="Y">
                    <LastName>Fink</LastName>
                    <ForeName>Jeffrey</ForeName>
                    <Initials>J</Initials>
                </Investigator>
                <Investigator ValidYN="Y">
                    <LastName>Appel</LastName>
                    <ForeName>Lawrence J</ForeName>
                    <Initials>LJ</Initials>
                </Investigator>
                <Investigator ValidYN="Y">
                    <LastName>Lash</LastName>
                    <ForeName>James P</ForeName>
                    <Initials>JP</Initials>
                </Investigator>
            </InvestigatorList>
        </MedlineCitation>
        <PubmedData>
            <History>
                <PubMedPubDate PubStatus="received">
                    <Year>2018</Year>
                    <Month>4</Month>
                    <Day>2</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="accepted">
                    <Year>2018</Year>
                    <Month>9</Month>
                    <Day>18</Day>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="pubmed">
                    <Year>2018</Year>
                    <Month>12</Month>
                    <Day>14</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="medline">
                    <Year>2019</Year>
                    <Month>12</Month>
                    <Day>27</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="entrez">
                    <Year>2018</Year>
                    <Month>12</Month>
                    <Day>15</Day>
                    <Hour>6</Hour>
                    <Minute>0</Minute>
                </PubMedPubDate>
                <PubMedPubDate PubStatus="pmc-release">
                    <Year>2020</Year>
                    <Month>3</Month>
                    <Day>1</Day>
                </PubMedPubDate>
            </History>
            <PublicationStatus>ppublish</PublicationStatus>
            <ArticleIdList>
                <ArticleId IdType="pubmed">30545708</ArticleId>
                <ArticleId IdType="mid">NIHMS1516396</ArticleId>
                <ArticleId IdType="pmc">PMC6812505</ArticleId>
                <ArticleId IdType="doi">10.1053/j.ajkd.2018.09.012</ArticleId>
                <ArticleId IdType="pii">S0272-6386(18)31039-4</ArticleId>
            </ArticleIdList>
            <ReferenceList>
                <Reference>
                    <Citation>Ross R Atherosclerosis--an inflammatory disease. New Eng J Medicine 1999;340(2):115&#x2013;126.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">9887164</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Gupta J, Mitra N, Kanetsky PA et al. Association between albuminuria, kidney function, and inflammatory biomarker profile. Clin J Am Soc Nephrol 2012;71938&#x2013;1946.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pmc">PMC3513744</ArticleId>
                        <ArticleId IdType="pubmed">23024164</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Kaptoge S, Seshasai SR, Gao P et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J 2014;35(9):578&#x2013;589.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pmc">PMC3938862</ArticleId>
                        <ArticleId IdType="pubmed">24026779</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Greenland P, Alpert JS, Beller GA et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010;56(25):e50&#x2013;103.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">21144964</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55(5):1899&#x2013;1911.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">10231453</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Zoccali C, Tripepi G, Mallamaci F. Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol 2006;17(12 Suppl 3):S169&#x2013;S173.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">17130257</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Knight EL, Rimm EB, Pai JK et al. Kidney dysfunction, inflammation, and coronary events: a prospective study. J Am Soc Nephrol 2004;15(7):1897&#x2013;1903.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">15213279</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Goff DC Jr., Lloyd-Jones DM, Bennett G et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S49&#x2013;S73.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24222018</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Feldman HI, Appel LJ, Chertow GM et al. The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol 2003;14(7 Suppl 2):S148&#x2013;S153.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">12819321</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Lash JP, Go AS, Appel LJ et al. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 2009;4(8):1302&#x2013;1311.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pmc">PMC2723966</ArticleId>
                        <ArticleId IdType="pubmed">19541818</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Amdur RL, Feldman HI, Gupta J et al. Inflammation and Progression of CKD: The CRIC Study. Clin J Am Soc Nephrol 2016;11(9):1546&#x2013;1556.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pmc">PMC5012490</ArticleId>
                        <ArticleId IdType="pubmed">27340285</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008;3(2):505&#x2013;521.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pmc">PMC6631093</ArticleId>
                        <ArticleId IdType="pubmed">18184879</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Kremers WK. Concordance for Survival Time Data Including Time-Dependent Covariates Accounting for Ties in Predictor and Time Technical Report. 2008. Mayo Clinic College of Medicine.</Citation>
                </Reference>
                <Reference>
                    <Citation>Gonen M. Analyzing receiver operating characteristic curves with SAS. 2007. Cary, NC, SAS Institute Inc.</Citation>
                </Reference>
                <Reference>
                    <Citation>Sung KC, Ryu S, Lee JY et al. Urine Albumin/Creatinine Ratio Below 30 mg/g is a Predictor of Incident Hypertension and Cardiovascular Mortality. J Am Heart Assoc 2016;5(9). e003245.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pmc">PMC5079007</ArticleId>
                        <ArticleId IdType="pubmed">27625343</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94496&#x2013;504.</Citation>
                </Reference>
                <Reference>
                    <Citation>Tonelli M, Wiebe N, Culleton B et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17(7):2034&#x2013;2047.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">16738019</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Manjunath G, Tighiouart H, Ibrahim H et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003;41(1):47&#x2013;55.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">12570944</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Baber U, Stone GW, Weisz G et al. Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. JACC Cardiovasc Imaging 2012;5(3 Suppl):S53&#x2013;S61.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">22421231</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Ponda MP, Barash I, Feig JE, Fisher EA, Skolnik EY. Moderate kidney disease inhibits atherosclerosis regression. Atherosclerosis 2010;210(1):57&#x2013;62.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pmc">PMC3175796</ArticleId>
                        <ArticleId IdType="pubmed">19931862</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Suganuma E, Zuo Y, Ayabe N et al. Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction. J Am Soc Nephrol 2006;17(2):433&#x2013;441.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">16371432</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Menon V, Greene T, Wang X et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005;68(2):766&#x2013;772.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">16014054</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Beddhu S, Kaysen GA, Yan G et al. Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis 2002;40(4):721&#x2013;727.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">12324906</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Nelson JJ, Liao D, Sharrett AR et al. Serum albumin level as a predictor of incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000;151(5):468&#x2013;477.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">10707915</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Kaptoge S, White IR, Thompson SG et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol 2007;166(8):867&#x2013;879.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">17785713</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Stouthard JM, Levi M, Hack CE et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996;76(5):738&#x2013;742.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">8950783</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Seino Y, Ikeda U, Ikeda M et al. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 1994;6(1):87&#x2013;91.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">8003639</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000; 102(21):2636&#x2013;2642.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">11085968</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108(17):2154&#x2013;2169.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">14581387</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560&#x2013;2572.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">12748199</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Duncan BB, Schmidt MI, Pankow JS et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003;52(7):1799&#x2013;1805.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">12829649</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Conen D, Ridker PM, Everett BM et al. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur Heart J 2010;31(14):1730&#x2013;1736.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pmc">PMC2903714</ArticleId>
                        <ArticleId IdType="pubmed">20501475</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Schlackow I, Kent S, Herrington W et al. A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. Heart 2017;103(23):1880&#x2013;1890.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pmc">PMC5749372</ArticleId>
                        <ArticleId IdType="pubmed">28780579</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Muntner P, Colantonio LD, Cushman M et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA 2014;311(14):1406&#x2013;1415.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pmc">PMC4189930</ArticleId>
                        <ArticleId IdType="pubmed">24682252</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr., et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014;370(15):1422&#x2013;1431.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">24645848</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Snaedal S, Heimburger O, Qureshi AR et al. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am J Kidney Dis 2009;53(6):1024&#x2013;1033.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pubmed">19394732</ArticleId>
                    </ArticleIdList>
                </Reference>
                <Reference>
                    <Citation>Kimmel PL, Phillips TM, Simmens SJ et al. Immunologic function and survival in hemodialysis patients. Kidney International 1998;54(1):236&#x2013;244.</Citation>
                    <ArticleIdList>
                        <ArticleId IdType="pmc">PMC6146918</ArticleId>
                        <ArticleId IdType="pubmed">9648084</ArticleId>
                    </ArticleIdList>
                </Reference>
            </ReferenceList>
        </PubmedData>
    </PubmedArticle>
</PubmedArticleSet>